COMP360 psilocybin safety research for trauma symptoms
About this title
Read the official source — NCT05312151Researchers studied Psilocybin, tracking side effects to assess safety and tolerability in people with PTSD.
Understand this study
What did researchers investigate?
Researchers studied Psilocybin, tracking side effects to assess safety and tolerability in people with PTSD.
Who was this study for?
This study was for people with PTSD. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Rockville and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- COMPASS Pathways
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom
- Age range
- Over 18 Years
- Official registry ID
- NCT05312151
- Official title
Show the full official title
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Rockville, United States · New York, United States · London, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Psilocybin, tracking side effects to assess safety and tolerability in people with PTSD.
Who is behind this study?
The study sponsor is COMPASS Pathways.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin.
Who was this study for?
This study was for people with PTSD. Listed age limits: from 18 years. Other eligibility criteria applied.
